cells in an MR1-restricted manner, and overrepresented mouse MAIT cells have an antibacterial potential in vivo. These reports therefore provide a critical physiological context for future studies of MR1 and MAIT cells.
I nterleukin-10 (IL-10) is well characterized as an anti-inflammatory cytokine, with potent suppressive effects in preventing autoimmune disease. 1 In the absence of IL-10, spontaneous mucosal autoimmunity develops, while the effect on systemic autoimmunity is far more muted. 2 In this issue of Immunology and Cell Biology, however, Lesage and colleagues 3 have uncovered an extra layer of complexity to the role of IL-10 in immune regulation.
Lesage and colleagues use a T-cell receptor transgenic system to track autoreactive T cells, specific for a pancreatic neo-antigen, that develop into CD4 À CD8 À 'double negative' (DN) T cells. These cells have the capacity to specifically lyse B cells loaded with neo-self antigens. 3 In a physiological setting, this is likely to reflect the suppression of autoreactive B cells that have internalised and presented the pancreatic self antigen. The antigen-specific activity of the DN T cells makes them particularly attractive as potential therapeutic mediators. Although autoimmune diabetes is not often thought of as an antibody-mediated disease, antibodies towards proinsulin predate and predict progression to clinical diabetes, 4 and anti-CD20 antibody-mediated B cell depletion shows some promise as a treatment. 5 The physiological relevance of DN T cells in autoimmune diabetes was previously demonstrated by the same group, as autoimmuneprone non-obese diabetic mice have a reduced number of DN T cells, and passive transfer of DN T cells prevents diabetes progression. 6 In this most recent advance, Hillhouse et al. 3 analysed the molecular basis for reduced DN T-cell numbers in non-obese diabetic mice. The authors found that ex vivo non-obese diabetic DN T cells have a 10-fold increase in IL-10 expression. In vitro, IL-10 had no impact on DN T-cell function or proliferation, but greatly accelerated apoptosis.
This new role for IL-10 is in contrast to its previously defined immunosuppressive roles, against both T H 1 and T H 2 immune responses. Although most cell types of both the adaptive and innate immune systems are capable of expressing IL-10 to various degrees, the key producers are Foxp3 + regulatory T (T REG ) cells. The mucosal autoimmunity that occurs in IL-10-deficient mice is essentially replicated by Foxp3 + T REG cellspecific ablation of IL-10. 7 This suggests that alternative sources of IL-10 production are of secondary importance in mucosal tolerance, although it does not exclude important roles for IL-10 derived from other sources under specialised conditions. IL-10 also further promotes its own production as well as the function of T REG cells, initiating a positive feedback loop for immune suppression via this key regulatory T-cell subset. 8 As DN T cells are suppressed via exposure to IL-10, this gives IL-10 opposing functions-amplifying one regulatory T cell population while actively suppressing another (Figure 1) .
These results, although surprising, potentially explain several discrepancies in the literature on IL-10. Although considered to be immunosuppressive in function, the use of IL-10 as a potential therapeutic has given mixed results, suggesting a more complex role in immune regulation. The effect of W Pierson and A Liston are at the Department of Experimental Medicine, VIB and University of Leuven, Leuven 3000, Belgium E-mail: adrian.liston@vib.be IL-10 on B cells, in particular, may be stimulatory rather than suppressive, as IL-10 enhances immunoglobulin production and elevates MHC class II expression on B cells. 9, 10 Although the stimulatory capacity may be relatively weak, especially in mouse B cells compared with human B cells, 9,10 the upregulation of MHC class II may necessitate a form of protection against DN T cells, which lyse B cells through MHC class II recognition. 3 The effect of IL-10 on B cells may therefore constitute both a direct stimulatory effect and an indirect protection from DN T cells, to allow effective stimulation of antibody responses.
In the case of autoimmune diabetes, both modes of IL-10 activity may be active. Systemic treatment with IL-10 through transgenic expression or subcutaneous injection protects against autoimmune diabetes. 11, 12 By contrast, transgenic expression of IL-10 in the pancreatic islets precipitates autoimmune diabetes, even on a resistant genetic background, and treatment with anti-IL-10 antibodies inhibits insulitis in non-obese diabetic mice. 13 Together, these findings suggest that systemic IL-10 has a net immunosuppressive function, possibly through the promotion of Foxp3 + T REG -mediated suppression, whereas local IL-10 production has a net immunostimulatory activity potentially through the amplification of DN T cell apoptosis (Figure 2) . Notably, the location of the primary function of each regulatory cell type may be the inverse of the location where IL-10 has its primary effect. That is, Foxp3 + T REG cells are of the greatest importance in suppressing autoreactive T cells within the inflamed islet, 14 whereas the greatest effect of DN T cells on autoreactive B cells is presumably within the draining lymphatics. If this model is correct, the timing and localization of IL-10 delivery during therapeutic treatment will be key to determining whether a beneficial or detrimental impact is achieved.
CONFLICT OF INTEREST
The authors declare no conflict of interest. 
